Swiss Psychedelic Research Update

MAPS Bulletin Spring 1992 Vol. 03, No. 2 Small Steps, Gradual Progress, New Opportunities

Download this article.

Several psychiatrists in the Swiss Association for Psycholytic Therapy (SAPT) have permission from the Swiss Health Office to continue to treat a limited number of patients with LSD and MDMA. In late January, the members of SAPT, who are primarily clinicians and not researchers, met with Professor Ladewig, a supervisor and consultant appointed by the Swiss Health Office to monitor their use of psychedelics. Professor Ladewig is helping the members of SAPT design a research protocol so that they can begin work with a larger number of patients. The design of the protocol is currently in process and is expected to be completed around the end of the summer